Diabetes Mellitus
By:
Holly J. Kramer Department of Public Health, Parkinson School of Health Sciences and Public Health and Department of Medicine, Division of Nephrology and Hypertension, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois

Search for other papers by Holly J. Kramer in
Current site
Google Scholar
PubMed Close
and
Sankar D. Navaneethan Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas Section of Nephrology, and Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas

Search for other papers by Sankar D. Navaneethan in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 18: Issue 4
Published Online:
Sep 2019
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand

Volume 18 (2019): Issue 4 (Sep 2019): Chronic Kidney Disease and Progression

in Nephrology Self-Assessment Program
Cover Nephrology Self-Assessment Program
Copyright:
© American Society of Nephrology 2019
Page Count:
6
Article Category:
Research Article
Print Publication Date:
01 Sep 2019
Published Online:
Sep 2019
  • 1.

    Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al.: Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA 316: 602–610, 2016 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Zelnick LR, Weiss NS, Kestenbaum BR, Robinson-Cohen C, Heagerty PJ, Tuttle K, et al.: Diabetes and CKD in the United States Population, 2009-2014. Clin J Am Soc Nephrol 12: 1984–1990, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Narva A: Population health for CKD and diabetes: Lessons from the Indian Health Service. Am J Kidney Dis 71: 407–411, 2018 PubMed

  • 4.

    Oellgaard J, Gæde P, Rossing P, Persson F, Parving HH, Pedersen O: Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int 91: 982–988, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    United States Renal Data System: 2017 USRDS data report. End-stage renal disease (ESRD) in the United States. Chapter 1: Incidence and prevalence, patient characteristics, and treatment modalities. 2017

    • PubMed
    • Export Citation
  • 6.

    Gerber C, Cai X, Lee J, Craven T, Scialla J, Souma N, et al.: Incidence and progression of chronic kidney disease in black and white individuals with type 2 diabetes. Clin J Am Soc Nephrol 13: 884–892, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    ACCORD Study Group: Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al.: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575–1585, 2010

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Gatwood J, Chisholm-Burns M, Davis R, Thomas F, Potukuchi P, Hung A, et al.: Evidence of chronic kidney disease in veterans with incident diabetes mellitus. PLoS One 13: e0192712, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Hung AM, Roumie CL, Greevy RA, Grijalva CG, Liu X, Murff HJ, et al.: Comparative effectiveness of second-line agents for the treatment of diabetes type 2 in preventing kidney function decline. Clin J Am Soc Nephrol 11: 2177–2185, 2016 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Nowak N, Skupien J, Smiles AM, Yamanouchi M, Niewczas MA, Galecki AT, et al.: Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int 93: 1198–1206, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Nair V, Komorowsky CV, Weil EJ, Yee B, Hodgin J, Harder JL, et al.: A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome. Kidney Int 93: 439–449, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Yamanouchi M, Skupien J, Niewczas MA, Smiles AM, Doria A, Stanton RC, et al.: Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. Kidney Int 92: 258–266, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Howse PM, Chibrikova LN, Twells LK, Barrett BJ, Gamble JM: Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: A systematic review and meta-analysis. Am J Kidney Dis 68: 733–742, 2016 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Navaneethan SD, Schold JD, Jolly SE, Arrigain S, Winkelmayer WC, Nally JV Jr: Diabetes control and the risks of ESRD and mortality in patients with CKD. Am J Kidney Dis 70: 191–198, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Alegre-Díaz J, Herrington W, López-Cervantes M, Gnatiuc L, Ramirez R, Hill M, et al.: Diabetes and cause-specific mortality in Mexico city. N Engl J Med 375: 1961–1971, 2016 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Voelker J, Berg PH, Sheetz M, Duffin K, Shen T, Moser B, et al.: Anti-TGF-β1 antibody therapy in patients with diabetic nephropathy. J Am Soc Nephrol 28: 953–962, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Prabhakar S, Starnes J, Shi S, Lonis B, Tran R: Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 18: 2945–2952, 2007 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Lau DH, Mikhailidis DP, Thompson CS: The effect of vardenafil (a PDE type 5 inhibitor) on renal function in the diabetic rabbit: A pilot study. In Vivo 21: 851–854, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Scheele W, Diamond S, Gale J, Clerin V, Tamimi N, Le V, et al.: Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy. J Am Soc Nephrol 27: 3459–3468, 2016 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Zinman B, Lachin JM, Inzucchi SE: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 374: 1094, 2016 PubMed

  • 21.

    Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al.; EMPA-REG OUTCOME Investigators: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323–334, 2016 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, et al.; EMPA-REG OUTCOME Investigators: Empagliflozin and kidney function decline in patients with type 2 diabetes: A slope analysis from the EMPA–REG OUTCOME trial. J Am Soc Nephrol 29: 2755–2769, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al.; EMPA-REG BP Investigators: Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38: 420–428, 2015 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Narva AS, Norton JM, Boulware LE: Educating patients about CKD: The path to self-management and patient-centered care. Clin J Am Soc Nephrol 11: 694–703, 2016 PubMed

Metrics

All Time Past Year Past 30 Days
Abstract Views 12 12 2
Full Text Views 9 9 1
PDF Downloads 13 13 2